{"entity":{"id":"nct06284317","kind":"trial","name":"A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Canc","aka":["ADOPT-lung"],"tldr":"A phase 3 trial in lung cancer, run by ETOP IBCSG Partners Foundation, now recruiting.","summary":"A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer. is a phase 3, randomised interventional study registered as NCT06284317 by ETOP IBCSG Partners Foundation, with a registry enrolment figure of 290 participants, started 2025-01-15 and due to reach its primary completion in 2029-10. Interventions recorded: Adjuvant durvalumab. Conditions listed: Non Small Cell Lung Cancer. Primary outcome: Disease-free survival (DFS). Lung eligibility wording from the registry: \"* Histologically confirmed NSCLC\". Sites: Australia, Austria, Belgium, Estonia, France, Ireland, Italy, Netherlands, Switzerland, United Kingdom. United Kingdom sites listed: 5. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT06284317","url":"https://clinicaltrials.gov/study/NCT06284317"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["resectable-nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["UK sites (registry): Barts Health NHS Trust (London); Royal Marsden Hospital (Chelsea) (London); Royal Marsden Hospital (Sutton) (London); Maidstone and Tunbridge Wells NHS Trust (Maidstone); Wythenshawe Hospital, Manchester University NHS Foundation Trust (Manchester)."],"nct":"NCT06284317","phase":"3","setting":"An International, Multicentre, Open-label Randomised Phase III Trial to Evaluate the Benefit of Adding Adjuvant Durvalumab After Neoadjuvant Chemotherapy Plus Durvalumab in Patients With Stage IIB-IIIB (N2) Resectable NSCLC","sponsor":"ETOP IBCSG Partners Foundation","enrolled":290,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06284317/","neighbours":{"cancer":[{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}